<h4>Background</h4>Immunotherapy targeting the programmed cell death (ligand)-1 (PD-[L]1) pathway has improved outcomes in patients with advanced/metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGAs), especially those with high PD-L1 expression (≥50% of tumor cells [TC]). The gene discussed is CD274; the disease is neoplasm.